文献速递治疗药物监测与药物基因组学特殊人群用药

CYP2C9*5变异等位基因患者的华法林剂量调整

Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
PubMed 文献 · Clin Pharmacol Ther · 2022-02-27

这项多中心研究纳入2298名服用华法林的患者(49%女性,35%黑人),量化CYP2C9*5等位基因与华法林剂量需求的关系。未纳入CYP2C9*5的药物遗传学算法在高加索人种中高估杂合子剂量30%(95%CI 19-40%,P<0.001),平均1.87 mg/天(SD 1.64)。CYP2C9*5基因分型可纠正潜在过量并减半杂合子总体剂量误差,携带者需临床相关剂量降低。

要点

  • CYP2C9*5几乎仅见于非洲裔人群,携带者需降低华法林剂量。
  • 未纳入CYP2C9*5的算法在杂合子中高估剂量30%,平均1.87 mg/天。
  • CYP2C9*5基因分型可纠正过量并减半剂量误差,已整合至WarfarinDosing.org。

核心结论

  • 携带CYP2C9*5等位基因的患者需要临床相关的华法林剂量降低。
  • 将CYP2C9*5纳入药物遗传学算法可提高非洲裔人群华法林剂量的准确性和安全性。

研究设计与样本

  • 多中心研究,纳入2298名服用华法林的患者,其中49%女性,35%黑人。
  • 量化CYP2C9*5等位基因与华法林需求量的关联。

主要发现

  • CYP2C9*5单核苷酸变异在黑人患者中占2.3%,在白人患者中占0.07%。
  • 未考虑CYP2C9*5时,包含其他SNV的药物遗传学算法在杂合子中高估华法林剂量30%(95%CI 19-40%,P<0.001),平均1.87 mg/天(SD 1.64)。
  • 非携带者所需剂量略高于预测剂量,平均高0.23 mg/天(SD 2.09)。
  • CYP2C9*5基因分型纠正了潜在过量,并将杂合子的总体剂量误差减半。

临床怎么用

  • 对非洲裔患者进行CYP2C9*5基因分型,以指导华法林起始剂量调整。
  • 可使用整合了CYP2C9*5的非营利网站www.WarfarinDosing.org辅助华法林起始剂量决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenetic dosing improves the accuracy of warfarin dosing, but current pharmacogenetic dosing algorithms are less accurate in populations of African ancestry. The cytochrome P450 2C9*5 (CYP2C9*5) allele is found almost exclusively in populations of African ancestry, and in vitro studies suggest CYP2C9*5 is associated with reduced clearance of warfarin. The clinical relevance of this single-nucleotide variation (SNV) (formerly SNP) is uncertain. In this multicentered study of 2,298 patients (49% female, 35% Black) taking warfarin, we quantified the association between the CYP2C9*5 allele and warfarin requirements. The CYP2C9*5 SNV was present in 2.3% of Black and 0.07% of White patients. Without taking CYP2C9*5 into account, pharmacogenetic algorithms that include other SNVs overestimated the warfarin dose by 30% (95% confidence interval (19-40%), P < 0.001), an average of 1.87 mg/day (SD 1.64) in heterozygotes (P < 0.001). Noncarriers required a slightly (0.23 mg/day, SD 2.09) higher than predicted dose. Genotyping for CYP2C9*5 corrected the potential overdose and halved overall dosing error in heterozygotes. Patients carrying CYP2C9*5 require a clinically relevant reduction in warfarin dose. Given the potential to improve the accuracy and safety of warfarin dosing in populations of African ancestry, we have incorporated this SNV into a nonprofit website to assist warfarin initiation (www.WarfarinDosing.org).

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lindley KJ, Limdi NA, Cavallari LH, et al. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles. Clin Pharmacol Ther. 2022. PMID: 35108398. doi:10.1002/cpt.2549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。